RxDoctor Payments Data

Emmanuel Gorospe

Gastroenterology · El Paso, TXNPI 1225160427

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,000 of the $4,523 with a category attached, or 66.3%. Eli Lilly accounts for 66.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $3,401 and has fallen 99.5% since, to $17 in 2023.

$4,523in general payments, 2019–2025

Across 55 payments — averaging $82.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3K
  • Ambu Inc.$527
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$272
  • Takeda Pharmaceuticals U.S.A., Inc.$136
  • Novartis$92
  • Biogen$73
  • plus $423 from 13 others
$2,282,964in research payments, 2019–2025

Across 114 payments — averaging $20,026 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$1.5M
  • Amgen$677K
  • Regeneron$70K
  • Bausch Health US, LLC$32K
  • GSK$19K

What the payments were for

  • Consulting fees$3,00066%
  • Food & beverage$1,52334%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,523 in reported general payments places this provider in the 55th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas →

Other gastroenterology in El Paso

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →